Industry
Biotechnology
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Loading...
Open
2.35
Mkt cap
7.9M
Volume
83K
High
2.38
P/E Ratio
-0.43
52-wk high
23.25
Low
2.25
Div yield
N/A
52-wk low
1.96
Portfolio Pulse from Benzinga Newsdesk
March 04, 2024 | 4:45 pm
Portfolio Pulse from Benzinga Newsdesk
February 08, 2024 | 12:03 pm
Portfolio Pulse from Avi Kapoor
January 19, 2024 | 6:05 pm
Portfolio Pulse from Benzinga Insights
January 19, 2024 | 5:31 pm
Portfolio Pulse from Benzinga Newsdesk
December 18, 2023 | 12:18 pm
Portfolio Pulse from Benzinga Newsdesk
November 29, 2023 | 12:10 pm
Portfolio Pulse from Benzinga Insights
November 17, 2023 | 1:07 pm
Portfolio Pulse from Benzinga Newsdesk
November 16, 2023 | 5:59 pm
Portfolio Pulse from Benzinga Insights
November 15, 2023 | 5:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.